G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by Needham & Company LLC

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating reissued by Needham & Company LLC in a note issued to investors on Friday, Benzinga reports. They currently have a $12.00 target price on the stock. Needham & Company LLC’s target price points to a potential upside of 163.74% from the company’s previous close.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th.

G1 Therapeutics Trading Down 2.8 %

NASDAQ GTHX opened at $4.55 on Friday. G1 Therapeutics has a one year low of $1.08 and a one year high of $5.00. The company’s 50 day moving average price is $3.67 and its 200 day moving average price is $2.79. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87. The firm has a market capitalization of $237.51 million, a price-to-earnings ratio of -4.79 and a beta of 1.73.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The company had revenue of $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. During the same quarter last year, the company earned ($0.73) earnings per share. On average, sell-side analysts predict that G1 Therapeutics will post -0.64 EPS for the current year.

Insider Transactions at G1 Therapeutics

In other news, insider Rajesh Malik sold 28,600 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.23% of the company’s stock.

Hedge Funds Weigh In On G1 Therapeutics

Several large investors have recently added to or reduced their stakes in GTHX. State Street Corp lifted its stake in G1 Therapeutics by 1,038.1% during the third quarter. State Street Corp now owns 1,618,381 shares of the company’s stock worth $20,214,000 after purchasing an additional 1,476,175 shares during the last quarter. FMR LLC lifted its stake in G1 Therapeutics by 246.3% in the first quarter. FMR LLC now owns 964,592 shares of the company’s stock valued at $2,585,000 after buying an additional 686,025 shares during the last quarter. Millennium Management LLC lifted its stake in G1 Therapeutics by 486.3% in the second quarter. Millennium Management LLC now owns 728,120 shares of the company’s stock valued at $3,597,000 after buying an additional 603,926 shares during the last quarter. Renaissance Technologies LLC lifted its stake in G1 Therapeutics by 531.9% in the fourth quarter. Renaissance Technologies LLC now owns 647,100 shares of the company’s stock valued at $3,514,000 after buying an additional 544,700 shares during the last quarter. Finally, abrdn plc bought a new stake in G1 Therapeutics in the fourth quarter valued at $1,293,000. 24.21% of the stock is currently owned by institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.